Clinical Trials Logo

Schwannomatosis clinical trials

View clinical trials related to Schwannomatosis.

Filter by:
  • None
  • Page 1

NCT ID: NCT05684692 Recruiting - Pain, Chronic Clinical Trials

Screening Trial for Pain Relief in Schwannomatosis (STARFISH)

Start date: August 31, 2023
Phase: Phase 2
Study type: Interventional

This is a placebo-controlled, multi-arm phase II platform screening trial designed to test the safety, pain responses, and pharmacodynamic activity of multiple experimental therapies simultaneously in participants with moderate-to-severe pain due to schwannomatosis (SWN). This Master Study is being conducted as a platform that may allow participants with pain associated with schwannomatosis to receive a novel intervention throughout this study. Embedded within the Master Study are individual drug sub-studies: - Investigational Drug Sub-Study A: Siltuximab - Investigation Drug Sub-Study B: Erenumab-Aooe

NCT ID: NCT04163419 Active, not recruiting - Pain Clinical Trials

Phase 2 Study of Tanezumab in Subjects With Moderate to Severe Pain Due to Schwannomatosis

Start date: April 30, 2020
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to determine whether the administration of tanezumab, an anti-nerve growth factor (NGF) antibody, improves pain relief in schwannomatosis patients receiving background non-NSAID therapy.

NCT ID: NCT03406208 Recruiting - Neurofibromatosis 1 Clinical Trials

Resiliency Training for Adults With Neurofibromatosis Via Live Videoconferencing

Start date: October 1, 2017
Phase: N/A
Study type: Interventional

The aims of this study are to compare the effect and durability of two stress and symptom management programs tailored for patients with neurofibromatosis on quality of life and psychosocial functioning.

NCT ID: NCT02298270 Completed - Neurofibromatosis 2 Clinical Trials

Resiliency Training for Patients With Neurofibromatosis Via Videoconferencing With Skype

Start date: March 2014
Phase: N/A
Study type: Interventional

This study tests the efficacy of an 8-week, Skype-based, group resiliency training intervention (The Relaxation Response Resiliency Program) for improving psychological stress in patients with Neurofibromatosis. A control group will receive a general health education curriculum. The investigators hypothesize that patients will improve on measures of psychological stress as a result of the resiliency program. A substudy (Unique Protocol ID: 2013P002605b) has been approved to test this study on a sub-population: patients with NF2 who are hard of hearing.

NCT ID: NCT01885767 Recruiting - Neurofibromatosis 1 Clinical Trials

Neurofibromatosis (NF) Registry Portal

Start date: June 2012
Phase:
Study type: Observational [Patient Registry]

The NF Registry is a database of patient-reported symptoms, treatments, and experiences with their neurofibromatosis disease. It is a contact registry to relay clinical trial opportunities to targeted patient subgroups, and to supply de-identified disease data to researchers. It has the potential to become a natural history resource.